Stockscreener 앱 받기
0.68
2.86%
-0.02
전일 마감가:
$0.70
열려 있는:
$0.6852
하루 거래량:
75,900
Relative Volume:
0.41
시가총액:
$11.52M
수익:
$4.03M
순이익/손실:
$24.32M
주가수익비율:
-0.1581
EPS:
-4.3008
순현금흐름:
$-45.76M
1주 성능:
-16.56%
1개월 성능:
-8.11%
6개월 성능:
-45.60%
1년 성능:
-66.67%
1일 변동 폭
$0.668
$0.7098
1주일 범위
$0.668
$0.8128
52주 변동 폭
$0.5719
$2.43
Pavmed Inc Stock (PAVM) Company Profile
명칭
Pavmed Inc
전화
(212) 949-4319
주소
360 MADISON AVENUE, NEW YORK, NY
PAVM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
0.68 | 11.52M | 4.03M | 24.32M | -45.76M | -4.3008 |
|
ABT
Abbott Laboratories
|
131.59 | 225.32B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.09 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
376.25 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.57 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.79 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-05 | 개시 | Ascendiant Capital Markets | Buy |
| 2018-06-28 | 개시 | Maxim Group | Buy |
Pavmed Inc 주식(PAVM)의 최신 뉴스
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
PAVmed outlines strategic milestones for 2025, including Veris implantable device submission - MSN
Pavmed’s Strategic Growth and Financial Challenges - MSN
PAVmed Inc. (NASDAQ:PAVM) Q4 2024 Earnings Call Transcript - Insider Monkey
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology - Nasdaq
PAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Growth and Financial Stability - Yahoo
PAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Gr - GuruFocus.com
PAVmed Reports Strong Q4 Results and Strategic Progress - TipRanks
Earnings call transcript: PAVmed Q4 2024 reports net income boost - Investing.com India
Earnings call transcript: PAVmed Q4 2024 reports net income boost By Investing.com - Investing.com South Africa
PAVmed Inc Surpasses Q4 2024 Revenue Estimates with $1.2 Million, Driven by Record EsoGuard Test Volume - GuruFocus
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - Placera.se
PAVmed Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PAVmed Achieves Triple Win: Record Tests, Insurance Coverage, Positive Income - Stock Titan
Lucid Diagnostics Reports Strong Growth and Future Plans - TipRanks
Lucid Diagnostics Achieves 84% Growth: EsoGuard Tests Hit All-Time High as Insurance Coverage Expands - Stock Titan
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening - The Malaysian Reserve
Lucid Diagnostics Announces Updated National Comprehensive Cance - GuruFocus
Major Breakthrough: NCCN Backs New Esophageal Cancer Testing Method, Insurance Coverage Expected to Expand - Stock Titan
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication - BioSpace
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® - GuruFocus.com
Clinical Study: New EsoGuard Test Detects Esophageal Cancer Risk 140% More Effectively - StockTitan
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test - The Malaysian Reserve
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test – Company AnnouncementFT.com - Financial Times
Major Breakthrough: Lucid Diagnostics Secures Game-Changing Insurance Coverage for Cancer Test - Stock Titan
Lucid Diagnostics Executes First Concierge Medicine Contract wit - GuruFocus.com
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Pri - GuruFocus.com
PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025 - Longview News-Journal
PAVmed CEO to Reveal Growth Strategy and Q4 Results in Upcoming Investor Call - Stock Titan
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025 - BioSpace
Midtown company tells investors esophageal pre-cancer screening should be an easier pill to swallow - Crain's New York Business
PAVmed, Inc. to Host Earnings Call - ACCESS Newswire
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering - BioSpace
Lucid Diagnostics secures $15.3 million in stock offering By Investing.com - Investing.com Australia
Lucid Diagnostics secures $15.3 million in stock offering - Investing.com
Lucid Diagnostics secures $15.3 million in stock sale By Investing.com - Investing.com Australia
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering - The Eastern Progress Online
SEC Form 424B5 filed by Lucid Diagnostics Inc. - Quantisnow
Insulet (NASDAQ:PODD) & PAVmed (NASDAQ:PAVM) Head-To-Head Review - Defense World
Lucid Diagnostics Announces $15.3 Million Registered Direct Offe - GuruFocus.com
Lucid Diagnostics ends "at the market" equity offering By Investing.com - Investing.com South Africa
Lucid Diagnostics ends "at the market" equity offering - Investing.com India
Lucid Diagnostics secures $15.3 million in stock sale - Investing.com
PAVmed Inc. (NASDAQ:PAVM) Short Interest Update - Defense World
Tasso Partners Reports 18.9% Passive Stake In PAVmed As Of Feb 21SEC Filing - Marketscreener.com
Can Lucid's Cancer Test Reach Millions More Patients? NIH Invests $8M to Find Out - StockTitan
Lucid Diagnostics meets Nasdaq minimum bid price rule By Investing.com - Investing.com Australia
Lucid Diagnostics Restores Nasdaq Listing Compliance - Nasdaq
Pavmed Inc (PAVM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.44%
0.15%
자본화:
|
볼륨(24시간):